<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01833325</url>
  </required_header>
  <id_info>
    <org_study_id>UFPTI 1206-EY01</org_study_id>
    <nct_id>NCT01833325</nct_id>
  </id_info>
  <brief_title>Proton Radiation Therapy for Macular Degeneration</brief_title>
  <official_title>A Pilot Study to Assess the Safety of Proton Therapy for Subfoveal Neovascularization Associated With Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study to determine if proton radiation therapy can provide effective and safe
      treatment for subfoveal neovascularization membrane (SNVM). The study will include adult
      patients over the age of 50 with macular degeneration, who have subfoveal neovascularization
      membrane (SNVM) and have had prior treatment with Avastin or Lucentis. Additional purposes of
      this study are to see if the growth of neovascular membranes can be stopped and overall
      vision improved with the use of protons and assess the side effects associated with this
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As part of this study, participants will have had a standard of care comprehensive eye exam
      by an Ophthalmologist to include visual acuity, fundus photography, fluorescein angiography
      and optical coherence tomography prior to treatment.

      Participants will receive radiation using protons for 2 consecutive days. Each treatment will
      take 30 minutes. They will receive a total dose of 24 cobalt gray equivalent (CGE) in 2
      treatments. A total of 10 participants will be enrolled on this study.

      A comprehensive eye exam by an Ophthalmologist will be performed 30 days after radiation
      treatment with protons. Additionally, a physical examination per a Radiation Oncologist
      including a toxicity evaluation and comprehensive eye exam by an Ophthalmologist will be
      performed every 3 months for 1 year following radiation treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with acute and late morbidity of the eye as a measure of safety</measure>
    <time_frame>1 year after completion of radiation treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with cessation of growth of neovascular membranes.</measure>
    <time_frame>1 year after completion of radiation treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity per comprehensive eye exam</measure>
    <time_frame>1 year after completion of radiation treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of intravitreal injections following radiation treatment</measure>
    <time_frame>1 year after completion of radiation treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Proton radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton radiation</intervention_name>
    <description>Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments</description>
    <arm_group_label>Proton radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with subfoveal neovascular membranes identified on fluorescein angiography.

          -  Visual acuity (best corrected vision) 20/200 or worse in affected eye.

          -  Patient must be 50 years of age or older at time of consent.

          -  Patients must have had prior treatment for macular degeneration with Avastin
             (bevacizumab) or Lucentis (ranibizumab).

          -  Women must be post menopausal or have had a hysterectomy.

        Exclusion Criteria:

          -  History of diabetes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roi Dagan, MD,</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida Proton Therapy Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Proton Therapy Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Macular Degeneration Foundation Adult Macular Degeneration. Available at: http://www.eyesight.org/Macular_Degeneration/Adult_MD/adult_md.html. Accessed March 8, 2012.</citation>
  </reference>
  <reference>
    <citation>Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1982 Jun;100(6):912-8.</citation>
    <PMID>7046707</PMID>
  </reference>
  <reference>
    <citation>Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1990 Jun;108(6):816-24.</citation>
    <PMID>1693496</PMID>
  </reference>
  <reference>
    <citation>Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001 Feb;119(2):198-207.</citation>
    <PMID>11176980</PMID>
  </reference>
  <reference>
    <citation>Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol. 1991 Sep;109(9):1220-31.</citation>
    <PMID>1718250</PMID>
  </reference>
  <reference>
    <citation>Chakravarthy U, Gardiner TA, Archer DB, Maguire CJ. A light microscopic and autoradiographic study of non-irradiated and irradiated ocular wounds. Curr Eye Res. 1989 Apr;8(4):337-48.</citation>
    <PMID>2721224</PMID>
  </reference>
  <reference>
    <citation>Plowman PN, Harnett AN. Radiotherapy in benign orbital disease. I: Complicated ocular angiomas. Br J Ophthalmol. 1988 Apr;72(4):286-8.</citation>
    <PMID>3378026</PMID>
  </reference>
  <reference>
    <citation>Macfaul PA, Bedford MA. Ocular complications after therapeutic irradiation. Br J Ophthalmol. 1970 Apr;54(4):237-47.</citation>
    <PMID>5310660</PMID>
  </reference>
  <reference>
    <citation>Guyer DR, Mukai S, Egan KM, Seddon JM, Walsh SM, Gragoudas ES. Radiation maculopathy after proton beam irradiation for choroidal melanoma. Ophthalmology. 1992 Aug;99(8):1278-85.</citation>
    <PMID>1325044</PMID>
  </reference>
  <reference>
    <citation>Chakravarthy U, Houston RF, Archer DB. Treatment of age-related subfoveal neovascular membranes by teletherapy: a pilot study. Br J Ophthalmol. 1993 May;77(5):265-73.</citation>
    <PMID>8318462</PMID>
  </reference>
  <reference>
    <citation>Yonemoto LT, Slater JD, Blacharski P, Archambeau JO, Loredo LN, Oeinck SC, Teichman S, Moyers M, Slater JM. Dose Response in the Treatment of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Results of a Phase I/II Dose-Escalation Study Using Proton Radiotherapy. Journal of Radiosurgery. 2000;3(1):47-54. DOI: 10.1023/A:1009525220716</citation>
  </reference>
  <reference>
    <citation>Zambarakji HJ, Lane AM, Ezra E, Gauthier D, Goitein M, Adams JA, Munzenrider JE, Miller JW, Gragoudas ES. Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology. 2006 Nov;113(11):2012-9. Epub 2006 Aug 28.</citation>
    <PMID>16935343</PMID>
  </reference>
  <reference>
    <citation>Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5;355(14):1432-44.</citation>
    <PMID>17021319</PMID>
  </reference>
  <reference>
    <citation>Sivagnanavel V, Evans JR, Ockrim Z, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004004. Review. Update in: Cochrane Database Syst Rev. 2010;(5):CD004004.</citation>
    <PMID>15495075</PMID>
  </reference>
  <reference>
    <citation>Park SS, Daftari I, Phillips T, Morse LS. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration. Retina. 2012 May;32(5):956-66. doi: 10.1097/IAE.0b013e31822a8d6a.</citation>
    <PMID>22183743</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>April 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>Macular Degeneration</keyword>
  <keyword>Proton radiation</keyword>
  <keyword>Choroidal Neovascular Membranes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

